Streetbeat News

Products Services

TGL

Treasure Global (TGL) has announced a strategic partnership with Silica-AI to enhance its AI and IoT capabilities, particularly in its ZCITY product. This collaboration is expected to tap into a $26.89 billion market opportunity, signaling significant growth potential for Treasure Global.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 1:10 pm

AMIX

Autonomix Medical has secured principal investigators and completed clinical training for its first human study, a proof-of-concept clinical trial targeting the pancreatic cancer market through transvascular RF ablation. The company expects to commence patient enrollment imminently, aiming at the multi-billion-dollar pancreatic cancer market.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 1:08 pm

ADI

TSM

Analog Devices (ADI) has entered into a special arrangement with TSMC to secure long-term wafer capacity through Japan Advanced Semiconductor Manufacturing, Inc, a majority-owned subsidiary of TSMC in Japan. This strategic move aims to ensure a stable supply of semiconductors for ADI, reflecting the importance of securing semiconductor supply chains in the current global market.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 1:08 pm

ABBV

AbbVie has entered into a collaboration with Tentarix to develop conditionally-active, multi-specific biologics for oncology and immunology, leveraging AbbVie's expertise and Tentarix's Tentacles platform. AbbVie will have an exclusive option to acquire the therapeutic programs after candidate nomination by Tentarix.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 1:06 pm

MYNZ

Mainz Biomed has announced a distribution partnership with Praxisdienst for its ColoAlert product, a diagnostic tool for early detection of colorectal cancer. This partnership aims to enhance the availability and accessibility of ColoAlert, potentially increasing Mainz Biomed's market presence and revenue from this product.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 1:05 pm

SLRX

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) is implementing cost-saving measures to extend its cash runway into the first half of 2025, supporting ongoing seclidemstat clinical trials for hematologic cancers and Ewing sarcoma. The company has seen encouraging results, with a 50% objective response rate in hematologic cancer trials and a 60% rate in Ewing sarcoma patients. CEO David Arthur transitions to a part-time consultant role to reduce expenses. Salarius continues to explore strategic alternatives with Canaccord Genuity, LLC to maximize shareholder value.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 1:05 pm

MDAI

Spectral AI, Inc. (NASDAQ:MDAI) has received UKCA authorization for its DeepView AI-Burn software, enabling the sale of its DeepView System in the UK for burn wound diagnosis. The company plans to deploy six devices in the UK for customer evaluation and expects to generate revenue in H2 2024. This authorization also facilitates expansion into the Middle East. The DeepView System, with a 92% accuracy rate, significantly improves upon the current standard of care for assessing burn wounds, which has a 50% to 75% accuracy rate.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 1:03 pm

USB

U.S. Bancorp, through its subsidiary U.S. Bank, has launched a new division aimed at providing services to private capital firms and global asset managers. This strategic move is designed to expand its offerings and cater to a niche yet significant segment of the financial market.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 1:02 pm

ICU

Seastar Medical Holding has received FDA approval for its Selective Cytopheretic Device (SCD) Pediatric for use in children weighing 10 kilograms or more with acute kidney injury due to sepsis or a septic condition requiring kidney replacement therapy. This approval marks a significant milestone for the company, potentially opening up new markets and enhancing its product portfolio in the medical device sector.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 12:56 pm

BPMC

RIGL

Rigel Pharmaceuticals has acquired the U.S. rights to GAVRETO from Blueprint Medicines for a $15M purchase price, with potential for up to $97.5M in commercial milestone payments and an additional $5M in future regulatory milestone payments. GAVRETO, an FDA approved therapy for certain cancers, generated approximately $28M in U.S. sales in 2023. This acquisition expands Rigel's portfolio and leverages its existing infrastructure.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 12:53 pm